Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure

Documenti analoghi

• Clinical Trial: Hepatitis B Virus Genotype and a Combination of End‐of‐Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation
  di: Arno Furquim d’Almeida, et al.
  Pubblicazione: (2025)
• Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’
  di: Dong Hyun Kim, et al.
  Pubblicazione: (2025)
• Letter on “Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China”
  di: Ersel Bilgin, et al.
  Pubblicazione: (2025)
• Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’—Authors' Reply
  di: Ning Yu, et al.
  Pubblicazione: (2025)
• Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono‐Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study
  di: Raffaella Viganò, et al.
  Pubblicazione: (2025)